Zenas BioPharma Grants 35,700 Options and 53,625 RSUs at $26.77
Zenas BioPharma granted non-qualified options for 35,700 shares and 53,625 RSUs to new hires on Feb 17, 2026, with a $26.77 exercise price equal to the closing share price. Options vest over four years (25% after one year, then monthly), while RSUs vest in four equal annual installments.
1. Inducement Grant Details
On Feb 17, 2026 the Compensation Committee granted non-qualified stock options to purchase 35,700 shares and 53,625 restricted stock units to newly hired employees under Nasdaq Listing Rule 5635(c)(4). The options carry a ten-year term and an exercise price of $26.77 per share, matching the closing price on the grant date.
2. Vesting and Potential Impact
The stock options vest over four years with 25% vesting on the one-year anniversary and the remaining 75% vesting in equal monthly installments over the next 36 months. The RSUs vest in four equal installments on February 15 of 2027, 2028, 2029 and 2030, subject to continued service, potentially diluting existing shareholders while aligning employee incentives with long-term growth.